Innovative therapeutics for high-burden CNS disorders

Current treatments for addiction, psychiatric, and neurological disorders remain limited, hard to access, and too often ineffective. With substantial personal, societal, and economic costs, the need for better solutions is urgent.

At Solvonis, we are developing novel therapeutics to address these challenges and bring new hope to patients. Our initial focus is on Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD), while our discovery programmes support expansion across Addiction and Psychiatry and evaluate a future entry point into Neurology.